⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Proteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003)

Bhaskar Roy Fatemeh Khani Habiabadi Kevin C. O’Connor Richard J. Nowak Henry J. Kaminski

View Full Paper

Ask AI

Bookmark

Share

Abstract

This exploratory in-depth proteomics analysis examined the differences in the immunopathogenesis of acetylcholine receptor (AChR) autoantibody-positive early onset (symptom onset < 50 years of age) and late-onset myasthenia gravis (EOMG and LOMG) utilizing the well-characterized BeatMG study (B-Cell Targeted Treatment in MG; NCT02110706) cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roy et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876780a5 https://doi.org/10.1212/wnl.0000000000205944

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Distinct Immunological Signature in Late‐Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study2025 · 6 citations
2Cellular immune endophenotypes separating early and late-onset myasthenia gravis2025
3Mendelian randomization followed by single-cell RNA sequencing exploration identifies effector memory CD4+ T cells as a risk factor for myasthenia gravisMendelian Randomization · 2026
4Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls2024 · 20 citations
5Late‐Onset Myasthenia Gravis: An Increasingly Frequent Clinical Entity With Distinctive ChallengesOriginal Research · 2026